Literature DB >> 11579441

Optimization of metabolic stability as a goal of modern drug design.

T N Thompson1.   

Abstract

Metabolism and other pharmacokinetic (PK) studies have always played a critical role in helping to optimize the bioavailability and duration of action of new drugs thereby increasing their success rate. With the advent of automated combinatorial synthesis, high-throughput pharmacological testing, and the ability to create extensive databases in the past decade, drug discovery has undergone an amazing evolution. With the increased throughput of drug discovery, metabolism and other PK studies have evolved to keep pace. Often called "early ADME" studies, these studies are characterized by parallel processing and higher throughput than before. This article focuses on a particular class of early ADME (absorption, distribution mechanism, and excretion) studies known as "metabolic stability" studies. The theoretical basis for metabolic stability and its relationship to the concept of metabolic intrinsic clearance is briefly presented. Some key relationships between structure and metabolism are summarized. Several case studies from recent medicinal chemistry literature are reviewed to exemplify how metabolic stability studies influenced drug design and led to improvements in bioavailability and half-life. Finally, future trends in drug metabolism and analytical chemistry and how they may influence metabolic stability studies are reviewed. Copyright 2001 John Wiley & Sons, Inc. Med Res Rev, 21, No. 5, 412-449, 2001

Mesh:

Substances:

Year:  2001        PMID: 11579441     DOI: 10.1002/med.1017

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  21 in total

1.  Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases.

Authors:  Z Yan; G W Caldwell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

2.  Prediction of in vitro metabolic stability of calcitriol analogs by QSAR.

Authors:  Berith F Jensen; Morten D Sørensen; Anne-Marie Kissmeyer; Fredrik Björkling; Kim Sonne; Søren B Engelsen; Lars Nørgaard
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

3.  Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.

Authors:  Stevan Pecic; Amir A Zeki; Xiaoming Xu; Gina Y Jin; Shuwei Zhang; Sean Kodani; Marlin Halim; Christophe Morisseau; Bruce D Hammock; Shi-Xian Deng
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-03-20       Impact factor: 3.072

Review 4.  Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.

Authors:  Collen M Masimirembwa; Ulf Bredberg; Tommy B Andersson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

6.  Ahp-Cyclodepsipeptide Inhibitors of Elastase: Lyngbyastatin 7 Stability, Scalable Synthesis, and Focused Library Analysis.

Authors:  Danmeng Luo; Hendrik Luesch
Journal:  ACS Med Chem Lett       Date:  2020-03-04       Impact factor: 4.345

7.  Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.

Authors:  Honghe Wan; Gretchen M Schroeder; Amy C Hart; Jennifer Inghrim; James Grebinski; John S Tokarski; Matthew V Lorenzi; Dan You; Theresa Mcdevitt; Becky Penhallow; Ragini Vuppugalla; Yueping Zhang; Xiaomei Gu; Ramaswamy Iyer; Louis J Lombardo; George L Trainor; Stefan Ruepp; Jonathan Lippy; Yuval Blat; John S Sack; Javed A Khan; Kevin Stefanski; Bogdan Sleczka; Arvind Mathur; Jung-Hui Sun; Michael K Wong; Dauh-Rurng Wu; Peng Li; Anuradha Gupta; P N Arunachalam; Bala Pragalathan; Sankara Narayanan; Nanjundaswamy K C; Prakasam Kuppusamy; Ashok V Purandare
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

8.  Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1.

Authors:  Yu Zhao; Qiong Gu; Susan L Morris-Natschke; Chin-Ho Chen; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2016-09-22       Impact factor: 7.446

9.  Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

Authors:  Nageshwar R Budha; Nitin Mehrotra; Rajendra Tangallapally; Jianjun Qi; Antwan J Daniels; Richard E Lee; Bernd Meibohm
Journal:  AAPS J       Date:  2008-03-14       Impact factor: 4.009

10.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.